Its effectiveness is verified in the diagnosis of atherosclerosis
A rapid breath test using "electronic nose" (eNose) technology developed at the Technion University in Haifa, northern Israel, was shown to be effective in verifying the diagnosis of atherosclerosis - a disease affecting the arteries - in patients.
The artificial nose uses sensitive, submicroscopic sensors, called nanoparticles, capable of detecting tiny molecular changes in the patient's blood.
The test can identify disease biomarkers and screen high-risk groups for specific diseases, as well as monitor treatments in people with that disease. The technology has already detected a variety of diseases, including certain types of cancer.... Read More: i24